Free Trial

EKF Diagnostics (LON:EKF) Shares Down 7% - Should You Sell?

EKF Diagnostics logo with Medical background

Key Points

  • EKF Diagnostics' stock fell by 7% during trading, reaching a low of GBX 23.60 ($0.31) before recovering slightly to GBX 26 ($0.35).
  • The company's most recent earnings report showed earnings per share (EPS) of GBX 0.43, with a net margin of 9.37% and a return on equity of 7.03%.
  • EKF Diagnostics has a market capitalization of £116.76 million and maintains solid liquidity ratios with a current ratio of 4.60 and a quick ratio of 1.77.
  • Interested in EKF Diagnostics? Here are five stocks we like better.

EKF Diagnostics Holdings plc (LON:EKF - Get Free Report) shares fell 7% during mid-day trading on Saturday . The company traded as low as GBX 23.60 ($0.31) and last traded at GBX 26 ($0.35). 2,281,890 shares traded hands during trading, an increase of 404% from the average session volume of 453,091 shares. The stock had previously closed at GBX 27.95 ($0.37).

EKF Diagnostics Stock Down 7.0%

The company has a current ratio of 4.60, a quick ratio of 1.77 and a debt-to-equity ratio of 0.34. The company has a market capitalization of £116.76 million, a PE ratio of 19.26 and a beta of 0.57. The business's 50-day simple moving average is GBX 29.18 and its 200-day simple moving average is GBX 26.59.

EKF Diagnostics (LON:EKF - Get Free Report) last posted its quarterly earnings results on Tuesday, September 16th. The company reported GBX 0.43 earnings per share (EPS) for the quarter. EKF Diagnostics had a net margin of 9.37% and a return on equity of 7.03%. As a group, equities research analysts anticipate that EKF Diagnostics Holdings plc will post 2.2987842 EPS for the current fiscal year.

About EKF Diagnostics

(Get Free Report)

EKF is an AIM-listed global diagnostics business focussed on: ● Point-of-Care analysers in the key areas of Hematology and Diabetes ● Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications. EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in EKF Diagnostics Right Now?

Before you consider EKF Diagnostics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and EKF Diagnostics wasn't on the list.

While EKF Diagnostics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report
Like this article? Share it with a colleague.